Total revenue grew 23% year-over-year driven by strong growth in both software and services Maintains full-year revenue guidance of $90 to $93 million and adjusted diluted EPS of $1.07 to $1.20 RESEARCH TRIANGLE PARK, N.C. / Apr 03, 2025 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions,... Read More

Conference call to be on Thursday, April 3, 2025, at 5 p.m. ET RESEARCH TRIANGLE PARK, N.C. / Mar 20, 2025 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that it will report second quarter fiscal 2025... Read More

RESEARCH TRIANGLE PARK, N.C. / Mar 10, 2025 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that Shawn O’Connor, Chief Executive Officer, will be participating in a fireside chat at the KeyBanc Capital Markets... Read More

RESEARCH TRIANGLE PARK, N.C. / Feb 04, 2025 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that it will participate in two healthcare investor conferences in February. The Company is attending the BTIG 12 th... Read More

Industry partners to provide funding and data to support ACAT™ model improvements RESEARCH TRIANGLE, N.C. / Jan 22, 2025 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that it has entered a new funded collaboration with the Enabling... Read More

SLP’s technology and expertise accelerates drug development and supports critical advancements in global healthcare RESEARCH TRIANGLE PARK, N.C. / Jan 13, 2025 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today highlighted its... Read More

Total revenue up 31% year-over-year primarily driven by strong software growth RESEARCH TRIANGLE PARK, N.C.--( BUSINESS WIRE )-- Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today reported financial results for its first quarter fiscal 2025, ended... Read More

Conference call to be on Tuesday, January 7, 2025, at 5 p.m. ET RESEARCH TRIANGLE PARK, N.C. / Dec 17, 2024 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications for the biopharma industry, today announced that it will report first quarter fiscal 2025 financial results after the... Read More

LANCASTER, Calif. / Nov 19, 2024 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications for the biopharma industry, today announced that Shawn O’Connor, chief executive officer, will participate in the virtual BTIG Digital Health Forum on Monday, November 25, 2024. Mr. O’Connor will... Read More

Funded collaboration will leverage current FDA partnership to include additional LAI technologies LANCASTER, Calif. / Nov 13, 2024 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that it has been awarded a newly funded grant from the... Read More

LANCASTER, Calif. / Nov 06, 2024 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that Shawn O’Connor, chief executive officer, will participate in a fireside chat at the Stephens Annual Investment Conference in Nashville, TN, on... Read More

Collaboration goal to develop alternative methods to assess clinical performance of product variants under different conditions LANCASTER, Calif. / Oct 30, 2024 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced a newly funded grant... Read More

Fiscal 2024 revenue grew 18% year-over-year to $70 million, with diluted earnings per share (EPS) of $0.49 Provides fiscal 2025 revenue guidance of $90 to $93 million (+28% to +33%) and adjusted diluted EPS guidance of $1.07 to $1.20 LANCASTER, Calif. / Oct 23, 2024 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence... Read More

Conference call to be on Wednesday, October 23, 2024, at 5 p.m. EDT LANCASTER, Calif. / Oct 09, 2024 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), announced today that it will report fourth quarter and fiscal 2024 financial results after the market close on Wednesday, October 23, 2024. Management will host a conference call that same day at 5:00 p.m. Eastern Time to discuss the results.... Read More

Partnership will advance the field of ligand-based virtual screening to improve drug design and optimization activities LANCASTER, Calif. / Oct 08, 2024 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced the award of a new research... Read More

LANCASTER, Calif. / Aug 28, 2024 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications for the biopharma industry, today announced that Shawn O’Connor, chief executive officer, will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference at the Marriott Marquis... Read More

Announces leadership appointments for newly structured business units LANCASTER, Calif. / Aug 23, 2024 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications for the biopharma industry, today announced the optimization of its business unit and leadership structure to support future... Read More

Updated quantitative systems toxicology (QST) software investigates and predicts drug-induced liver injury (DILI) LANCASTER, Calif. / Aug 01, 2024 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, has released the latest version of its flagship... Read More

Enhancements in key models power HT-PBPK simulations and AI-driven drug design with unprecedented performance and accuracy LANCASTER, Calif. / Jul 30, 2024 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced the release of version 12.0... Read More

LANCASTER, Calif. / Jul 25, 2024 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications for the biopharma industry, today announced that Shawn O’Connor, chief executive officer, will attend KeyBanc Capital Markets’ 25 th Annual Technology Leadership Forum on Monday, August 5, 2024,... Read More

Objective to define best practices for the use of novel PBK modeling strategies to support animal-free safety assessment of new chemicals LANCASTER, Calif. / Jul 11, 2024 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced a newly funded... Read More

Total revenue of $18.5 million and diluted earnings per share (EPS) of $0.15 Maintains full-year revenue guidance of $69 to $72 million and updates EPS guidance LANCASTER, Calif. / Jul 02, 2024 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications for the biopharma industry, today... Read More

LANCASTER, Calif. / Jun 20, 2024 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications for the biopharma industry, today announced that Shawn O’Connor, chief executive officer, will participate in the Morgan Stanley 3 rd Annual Life Sciences AI Summit on Wednesday, June 26, 2024,... Read More

Conference call to be on Tuesday, July 2, 2024, at 5 p.m. EDT LANCASTER, Calif. / Jun 18, 2024 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), announced today that it will report third quarter fiscal 2024 financial results after the market close on Tuesday, July 2, 2024. Management will host a conference call that same day at 5:00 p.m. Eastern Time to discuss the results. Investment professionals... Read More

Acquisition doubles the Company’s TAM to $8 billion Expected to be accretive to fiscal 2025 EPS Conference call at 5:00PM ET to discuss transaction LANCASTER, Calif. / Jun 12, 2024 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced the acquisition of Pro-ficiency Holdings, Inc.... Read More

LANCASTER, Calif. / May 22, 2024 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that Shawn O’Connor, chief executive officer, will participate in Craig-Hallum’s 21 st Annual Institutional Investor Conference on Wednesday, May 29, 2024, in... Read More

Redesigned platform offers ease-of-use, enhanced software engineering, and significant productivity gains for users LANCASTER, Calif. / May 15, 2024 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced the release of GastroPlus® X . Branded as GPX™, this new platform... Read More

Predicting DILI risk supports informed decision-making regarding drug evaluations and approvals LANCASTER, Calif. / Apr 04, 2024 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that the U.S. FDA has renewed its licenses to the DILIsym® software platform. DILIsym is... Read More

Total revenue of $18.3 million and diluted earnings per share (EPS) of $0.20 Maintains full-year revenue guidance of $66 to $69 million (+10-15%) and EPS guidance of $0.66 to $0.68 LANCASTER, Calif. / Apr 03, 2024 / Business Wire / Simulations Plus, Inc. (NASDAQ: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today reported financial... Read More

Conference call to be on Wednesday, April 3, 2024, at 5 p.m. EDT LANCASTER, Calif. / Mar 20, 2024 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), announced today that it will report second quarter fiscal 2024 financial results after the market close on Wednesday, April 3, 2024. Management will host a conference call that same day at 5:00 p.m. Eastern Time to discuss the results. Investment... Read More

LANCASTER, Calif. / Mar 13, 2024 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that Shawn O’Connor, chief executive officer, will be hosting a fireside chat at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum on Wednesday, March 20, 2024, at 4:30... Read More

Partnership will produce an enhanced, validated dermal PBBM/PBPK model to inform product development and bioequivalence decisions LANCASTER, Calif. / Mar 05, 2024 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that, through a joint proposal with the University of... Read More

Research project with NIEHS includes focus on qualification of in silico methods for prioritization, assessment of risk, and identification of safety margins for chemical use LANCASTER, Calif. / Feb 15, 2024 / Business Wire / Simulations Plus, Inc . (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today... Read More

Strategic investments in early-stage companies to drive innovation and collaboration LANCASTER, Calif. / Feb 13, 2024 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today provided additional information on advancing its corporate allocation strategy, specifically increased focus on... Read More

LANCASTER, Calif. / Feb 06, 2024 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that it will participate in two healthcare conferences in February. The Company will be presenting at Oppenheimer’s 34 th Annual Healthcare Life Sciences Conference taking place virtually from February 13-14, 2024.... Read More

New version delivers on FDA collaborations and user feedback for expansion of non-oral delivery route models LANCASTER, Calif. / Jan 30, 2024 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced the release of GastroPlus® 9.9, the latest version of its flagship... Read More

Partnership aims to integrate experimental data and PBPK modeling to identify key formulation factors to accelerate modified-release product development LANCASTER, Calif. / Jan 09, 2024 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that, through a joint proposal... Read More

LANCASTER, Calif. / Jan 03, 2024 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced the following leadership changes effective January 3, 2024. “We are excited to announce key strategic appointments that will advance our objective to seamlessly and organically align with our... Read More

Total revenue of $14.5 million and diluted earnings per share (EPS) of $0.10 Maintains full-year revenue guidance of $66 to $69 million (+10-15%) and EPS guidance of $0.66 to $0.68 LANCASTER, Calif. / Jan 03, 2024 / Business Wire / Simulations Plus, Inc. (NASDAQ: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today reported financial... Read More

Conference call to be on Wednesday, January 3, 2024, at 5 p.m. EST LANCASTER, Calif. / Dec 20, 2023 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), announced today that it will report first quarter fiscal 2024 financial results after the market close on Wednesday, January 3, 2024. Management will host a conference call that same day at 5:00 p.m. Eastern Time to discuss the results. Investment... Read More

Demonstrates How Putting Clients First Drives Growth and Fuels Innovation Reiterates 2024 Guidance LANCASTER, Calif. / Nov 14, 2023 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today will host its investor day virtually, as previously announced. Chief Executive Officer Shawn O’Connor,... Read More

Amparo de la Peña, Vice President of Pharmacometrics at Simulations Plus, will join Jeff Sachs, Pavan Vaddady and Hao Zhu as new board members for 2024 LANCASTER, Calif. / Nov 08, 2023 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical and biotechnology industries, announced today that Amparo de la Peña , Vice President of Pharmacometrics,... Read More

LANCASTER, Calif. / Oct 31, 2023 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it will hold a virtual Investor Day on Tuesday, November 14, 2023, beginning at 1:00 p.m. Eastern time. Presentations will be given by CEO Shawn... Read More

Fiscal 2023 revenue increased 11% year-over-year to $59.6 million Provides Fiscal 2024 revenue guidance of $66 - $69 million (+10-15%) and EPS guidance of $0.66 - $0.68 Simulations Plus to host its Investor Day on November 14, 2023 LANCASTER, Calif. / Oct 25, 2023 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical drug discovery and... Read More

Conference call to be on Wednesday, October 25, 2023, at 5 p.m. EDT LANCASTER, Calif. / Oct 11, 2023 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), announced today that it will report fourth quarter and fiscal 2023 financial results after the market close on Wednesday, October 25, 2023. Management will host a conference call that same day at 5:00 p.m. Eastern Time to discuss the results.... Read More

Collaboration with regulatory, industry, and academic partners will support and accelerate the development and validation of workflows to conduct virtual bioequivalence studies LANCASTER, Calif. / Sep 21, 2023 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced it has... Read More

Immersive activities helped attendees globally learn and apply best practices for PBPK modeling LANCASTER, Calif. / Sep 07, 2023 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical and biotechnology industries, announced the successful completion of the inaugural University+ PBPK Summer Camp, an intensive eight-week course covering the theory... Read More

Dr. Lukacova’s outstanding contributions to pharmaceutical research and innovation to be recognized with seven others at AAPS PharmSci 360 LANCASTER, Calif. / Aug 24, 2023 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical and biotechnology industries, is proud to announce that Dr. Viera Lukacova , Chief Science Officer of the SLP Division,... Read More

Elevated ALT levels during clinical trials led researchers to use quantitative systems toxicology (QST) software to better understand potential underlying mechanisms LANCASTER, Calif. / Aug 15, 2023 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today shared an article published in the July 2023 issue of... Read More

New functionality, models, and partner data power predictive accuracy from the industry-leading machine learning platform LANCASTER, Calif. / Jul 13, 2023 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical and biotechnology industries, today announced the release of ADMET Predictor® 11, its flagship machine learning modeling platform. The... Read More

Total revenue of $16.2 million and diluted earnings per share (EPS) of $0.20 Maintains full-year revenue guidance of $59.3 - $62.0 million (+10-15%) and EPS guidance of $0.63 - $0.67 LANCASTER, Calif. / Jul 06, 2023 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical drug discovery and development, today reported financial results for... Read More

Conference call to be on Thursday, July 6, 2023, at 5 p.m. EDT LANCASTER, Calif. / Jun 21, 2023 / Business Wire / Simulations Plus, Inc . (Nasdaq: SLP) (“Simulations Plus”), announced today that it will report third quarter fiscal 2023 financial results after the market close on Thursday, July 6, 2023. Management will host a conference call that same day at 5:00 p.m. Eastern Time to discuss the results. Investment... Read More

Acquisition increases breadth and depth of QSP expertise and range of therapeutic applications LANCASTER, Calif. / Jun 20, 2023 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced the acquisition of Immunetrics, Inc. (“Immunetrics”), a modeling and simulation company focused on... Read More

LANCASTER, Calif. / May 10, 2023 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced the release of a new integrated pulmonary software and services package. This targeted package will support pharmaceutical companies by streamlining their pulmonary drug development processes, enabling them to make... Read More

Provides FDA with software tools to investigate drug-induced liver injury in clinical trials LANCASTER, Calif. / Apr 18, 2023 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that the U.S. FDA has renewed its licenses to the DILIsym ® software platform, the flagship quantitative systems... Read More

Total revenue of $15.8 million; Diluted Earnings Per Share (EPS) of $0.20; Maintains full-year revenue guidance of $59.3 - $62.0 million (+10-15%) and EPS Guidance of $0.63 - $0.67 LANCASTER, Calif. / Apr 05, 2023 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today reported financial results for its second... Read More

LANCASTER, Calif. / Mar 30, 2023 / Business Wire / More than 150 people from around the world gathered virtually this past February for a panel discussion about how to move the needle on gender equity for women in science. Hosted by Simulations Plus, Inc. (Nasdaq: SLP) as part of their third annual Model-Informed Drug Development (MIDD+) conference, the speakers looked noticeably different than years prior: men were invited... Read More

Drug discovery services partnership with Sino-American Cancer Foundation focuses on the development of actionable hits against the MTHFD2 target LANCASTER, Calif. / Mar 28, 2023 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that it established a strategic research collaboration with the... Read More

Conference call to be on Wednesday, April 5, 2023, at 5 p.m. EDT LANCASTER, Calif. / Mar 21, 2023 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP), announced today that it will report financial results for the second quarter of fiscal year 2023, the period ended February 28, 2023, after the close of the financial markets on Wednesday, April 5, 2023. The Company will host a conference call on April 5, 2023, at 5:00 p.m.... Read More

LANCASTER, Calif. / Mar 16, 2023 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that chief executive officer Shawn O’Connor will be presenting at the Sidoti Small-Cap Investor Conference taking place virtually on March 22-23, 2023. Mr. O’Connor will be presenting on Thursday, March 23, 2023, at... Read More

LANCASTER, Calif. / Mar 15, 2023 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that it entered into a collaborative research agreement with the Institute of Medical Biology of the Polish Academy of Sciences (IMB PAS) to jointly design new compounds for the RORγ/RORγT nuclear receptors using... Read More

LANCASTER, Calif. / Mar 09, 2023 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that its Lixoft division, a leading provider of population PKPD modeling solutions for pharmacometricians and biostatisticians, has released version 2023R1 of its MonolixSuite™ software. Key advancements in this new... Read More

LANCASTER, Calif. / Mar 07, 2023 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that management will be presenting at Oppenheimer’s 33 rd Annual Healthcare Conference taking place virtually from March 13-15, 2023. Shawn O’Connor, chief executive officer, will be presenting on Tuesday, March 14,... Read More

LANCASTER, Calif. / Feb 16, 2023 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced it has entered a new collaboration with a large agrochemicals company to extend the industry’s top-rated machine learning model for the prediction of ionization constants (pK a ) in the ADMET Predictor ® platform.... Read More

LANCASTER, Calif. / Feb 09, 2023 / Business Wire / Simulations Plus, Inc . (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced the release of NAFLDsym v2B Beta, a quantitative systems pharmacology (QSP) modeling software to support the development of treatments for nonalcoholic steatohepatitis (NASH). This release focused solely on updates... Read More

DSX is faster, more user-friendly, and scalable for high-performance computing Simulations Plus , Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that its DILIsym Services (DSS) division has released DILIsym ® version X (DSX) Beta, the latest version of its flagship quantitative systems toxicology (QST) software for predicting and... Read More

Initiates first steps in updated capital allocation strategy Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced it has entered into an accelerated share repurchase agreement (the “ASR Agreement”) with Morgan Stanley & Co. LLC. to repurchase an aggregate of $20 million of the Company’s outstanding common shares. The... Read More

Total revenue of $12 million; Diluted Earnings Per Share (EPS) of $0.06; Both in line with fiscal 2023 guidance and Q1 expectations for revenue seasonality shift Provides capital allocation strategy update focusing on corporate development activities, $50 million share repurchase program, and internal investment Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for... Read More